The total return over the past 12 months is -30.15% vs. +16.94% for the S&P 500. So far it's up -0.14% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (30.15%) | +74.89% | (30.33%) | (16.49%) | (3.25%) | (7.95%) |
| Total Return CAGR | (30.15%) | +74.89% | (30.33%) | (16.49%) | (3.25%) | (7.95%) |
| Revenue CAGR | (27.15%) | (14.63%) | (12.34%) | (11.77%) | (4.67%) | (5.19%) |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Nektar Therapeutics (NKTR)
| Year | Start price | End price | NKTR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $42.28 | $42.22 | (0.14%) | +14.51% | (14.65%) |
| 2025 | $13.95 | $42.28 | +203.08% | +17.72% | +185.36% |
| 2024 | $8.48 | $13.95 | +64.50% | +24.89% | +39.61% |
| 2023 | $33.90 | $8.48 | (74.99%) | +26.19% | (101.18%) |
| 2022 | $202.65 | $33.90 | (83.27%) | (18.17%) | (65.10%) |
| 2021 | $255.00 | $202.65 | (20.53%) | +28.74% | (49.27%) |
| 2020 | $323.85 | $255.00 | (21.26%) | +18.37% | (39.63%) |
| 2019 | $493.05 | $323.85 | (34.32%) | +31.22% | (65.54%) |
| 2018 | $895.80 | $493.05 | (44.96%) | (4.56%) | (40.40%) |
| 2017 | $184.05 | $895.80 | +386.72% | +21.70% | +365.02% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
